Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2000-12-18
pubmed:abstractText
Chemokines provide signals for activation and recruitment of effector cells into sites of inflammation, acting via specific G protein-coupled receptors. However, in vitro data demonstrating the presence of multiple ligands for a given chemokine receptor, and often multiple receptors for a given chemokine, have led to concerns of biologic redundancy. Here we show that acute cardiac allograft rejection is accompanied by progressive intragraft production of the chemokines interferon (IFN)-gamma-inducible protein of 10 kD (IP-10), monokine induced by IFN-gamma (Mig), and IFN-inducible T cell alpha chemoattractant (I-TAC), and by infiltration of activated T cells bearing the corresponding chemokine receptor, CXCR3. We used three in vivo models to demonstrate a role for CXCR3 in the development of transplant rejection. First, CXCR3-deficient (CXCR3(-/)-) mice showed profound resistance to development of acute allograft rejection. Second, CXCR3(-/)- allograft recipients treated with a brief, subtherapeutic course of cyclosporin A maintained their allografts permanently and without evidence of chronic rejection. Third, CXCR(+/+) mice treated with an anti-CXCR3 monoclonal antibody showed prolongation of allograft survival, even if begun after the onset of rejection. Taken in conjunction with our findings of CXCR3 expression in rejecting human cardiac allografts, we conclude that CXCR3 plays a key role in T cell activation, recruitment, and allograft destruction.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-10556837, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-10587518, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-10619859, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-10699158, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-10714678, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-10762220, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-10799902, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-11007352, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-2443596, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-6232202, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-6232203, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-7507411, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-7595201, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-8476424, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-8798467, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-8943044, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-9064356, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-9625760, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-9653165, http://linkedlifedata.com/resource/pubmed/commentcorrection/11085753-9846576
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0022-1007
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
192
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1515-20
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Requirement of the chemokine receptor CXCR3 for acute allograft rejection.
pubmed:affiliation
Millennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139, USA. whanock@mpi.com
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.